2018 Press Releases

Press Releases | In the News

This section and the included press releases are presented for historical purposes only. Press releases and other documents speak only as of the date thereof.

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle
04/12/18Novan Advances Organization and Strengthens Leadership Team
CEO Role No Longer “Interim” Clinical Operations Role Established Finance Team Positioned for the Future MORRISVILLE, N.C., April 12, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced a number of key leadership and talent advancements that add to the existing foundation of the Company and enable its continued progress across key areas. Kelly Martin, who was appointed interim Chief Executive Officer (CEO) in June of 2017, will no longer be... 
03/29/18Novan Announces Corporate Update Conference Call and Webcast
MORRISVILLE, N.C., March 29, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that the Company will host a conference call on Thursday, April 12, at 8:30 a.m. Eastern Time to provide an update on the Company’s activities and progress. A moderated question and answer session will be available after the update. Callers should dial in approximately 10 minutes prior to the start of the call. No reservation is necessary to participate on the call. The ph... 
02/21/18Dr. Eugene Sun Appointed to Novan Board of Directors
Complements existing Board expertise as 30-year clinician, drug developer and former biopharmaceutical CEO Will provide expert perspective on the clinical application of the underlying nitric oxide science Will chair newly formed Research and Development Committee   MORRISVILLE, N.C., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that Eugene Sun, M.D., has been appointed to the Company’s Board of Directors, effective Feb... 
02/13/18Novan to Present Integrated Data from Phase 3 Trials with SB204 for Treatment of Acne
Late-breaking Presentation by Dr. Adelaide Hebert at 2018 AAD Annual Meeting MORRISVILLE, N.C., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that data from the Company’s two Phase 3 clinical trials and long-term safety trial with SB204 for the treatment acne vulgaris will be presented during a Late-breaking Research forum at the 2018 Annual Meeting of the American Academy of Dermatology, or AAD, in San Diego, California. Newly repor... 
01/25/18Novan Announces First Patient Dosed in Phase 2 Molluscum Contagiosum Trial with SB206
MORRISVILLE, N.C., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that the first patient has been dosed in the Company's Phase 2 clinical trial to evaluate topical nitric oxide product candidate SB206 for the treatment of molluscum contagiosum, a contagious skin infection caused by the molluscipoxvirus. There is currently no FDA-approved treatment for the molluscum indication."Broadening Novan's clinical development pipeline to include the ... 
01/11/18Novan Announces Closing of Offering of Common Stock and Warrants
MORRISVILLE, N.C., Jan. 11, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company" or "Novan") (NASDAQ:NOVN) today announced that it has closed its previously announced underwritten public offering.  The terms of the completed offering are consistent with the terms which were outlined in the Company's press release on January 5, 2018.  The net proceeds to the Company from this offering are expected to be approximately $35.2 million, after deducting underwriting discounts and commissions and ot... 
01/11/18Novan to Present Positive Phase 2 Results for SB208 Antifungal Program at Winter Clinical Dermatology Conference
Topical Nitric Oxide-Releasing Gel Shows Antifungal Activity in Tinea Pedis Infections MORRISVILLE, N.C., Jan. 11, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that Phase 2 efficacy and safety data for SB208, a topical, silicone-based gel under development for the treatment of fungal infections of the skin and nails, such as tinea pedis, or athlete’s foot, and onychomycosis, will be presented at the Winter Clinical Dermatology Conference to be ... 
01/05/18Novan Announces Pricing of $38.0 Million Offering of Common Stock and Warrants
MORRISVILLE, N.C., Jan. 05, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced the pricing of the Company's underwritten offering of 10 million shares of its common stock and accompanying warrants to purchase up to 10 million shares of common stock with an exercise price of $4.66. The shares and warrants are being sold at a public offering price of $3.80 per share and accompanying warrant. The gross proceeds from this offering to Novan are expected to... 
01/04/18Novan Announces Proposed Public Offering of Common Stock and Warrants
MORRISVILLE, N.C., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and accompanying warrants to purchase shares of common stock in an underwritten public offering. Piper Jaffray & Co. is acting as the sole book-running manager for the offering. The securities described above are being offered by Novan pursuant to a shelf registrat...